Evidence map›Paper›PMID 34452175›Full record

ReviewPharmaceutics2021

The Pharmaceutical Technology Approach on Imaging Innovations from Italian Research.

Giorgia Ailuno, Rosa Maria Iacobazzi, Antonio Lopalco, Sara Baldassari, Ilaria Arduino, Amalia Azzariti, Sara Pastorino, Gabriele Caviglioli, Nunzio Denora

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Radiolabeled Liposomes for Nuclear Imaging Probes.Molecules (Basel, Switzerland) · 2023
    Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giorgia AilunoDepartment of Pharmacy, University of Genova, Viale Cembrano 4, 16148 Genova, Italy.ORCID 0000-0002-2234-1805
Rosa Maria IacobazziLaboratory of Experimental Pharmacology, IRCCS Istituto Tumori "Giovanni Paolo II", O. Flacco St., 70124 Bari, Italy.ORCID 0000-0002-0737-6591
Antonio LopalcoDepartment of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", Orabona St. 4, 70125 Bari, Italy.ORCID 0000-0003-2124-9211
Sara BaldassariDepartment of Pharmacy, University of Genova, Viale Cembrano 4, 16148 Genova, Italy.ORCID 0000-0003-4602-6954
Ilaria ArduinoDepartment of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", Orabona St. 4, 70125 Bari, Italy.
Amalia AzzaritiLaboratory of Experimental Pharmacology, IRCCS Istituto Tumori "Giovanni Paolo II", O. Flacco St., 70124 Bari, Italy.
Sara PastorinoNuclear Medicine Unit, S. Andrea Hospital, via Vittorio Veneto 197, 19124 La Spezia, Italy.
Gabriele CaviglioliDepartment of Pharmacy, University of Genova, Viale Cembrano 4, 16148 Genova, Italy.
Nunzio DenoraDepartment of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", Orabona St. 4, 70125 Bari, Italy.ORCID 0000-0002-7756-7828

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many modern therapeutic approaches are based on precise diagnostic evidence, where imaging procedures play an essential role. To date, in the diagnostic field, a plethora of agents have been investigated to increase the selectivity and sensitivity of diagnosis. However, the most common drawbacks of conventional imaging agents reside in their non-specificity, short imaging time, instability, and toxicity. Moreover, routinely used diagnostic agents have low molecular weights and consequently a rapid clearance and renal excretion, and this represents a limitation if long-lasting imaging analyses are to be conducted. Thus, the development of new agents for in vivo diagnostics requires not only a deep knowledge of the physical principles of the imaging techniques and of the physiopathological aspects of the disease but also of the relative pharmaceutical and biopharmaceutical requirements. In this scenario, skills in pharmaceutical technology have become highly indispensable in order to respond to these needs. This review specifically aims to collect examples of newly developed diagnostic agents connoting the importance of an appropriate formulation study for the realization of effective products. Within the context of pharmaceutical technology research in Italy, several groups have developed and patented promising agents for fluorescence and radioactive imaging, the most relevant of which are described hereafter.

Indexed as

diagnosisformulationsimagingnanosystemnuclear medicineradiotracerstumor diagnosistumor imaging

Identifiers

PMID34452175
PMCPMC8402236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.